Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rasagiline as a Disease-Modifying Therapy in Early Parkinson's Disease
2005-001416-42Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Jun 2005
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rasagiline in Parkinson's disease (PD) (2 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Change from baseline in total UPDRS score. Started Jun 2005; status: completed.
02
Drugs
rasagiline
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2005-001416-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001416-42.